EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries

Murtuza Bharmal iD, Ioannis Katsoulis, Jane Chang, Alex Graham, Apostolina Stavropoulou, Priti Jhingran, Chris L Pashos iD

Future Oncology · 2024

DOI: 10.2217/fon-2023-1004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2024. Verfasst von Murtuza Bharmal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Global Evidence & Value Development Oncology, EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA. Hauptthemen laut MEDLINE: Medical Oncology, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck (CrossRef Funder ID: 10.13039/100009945), Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study explored the perceived value of real-world evidence (RWE) in the reassessment of oncology therapies by collecting the perspectives of health technology assessment/payer decision-makers.Materials & methods: A web-based survey was conducted using the Market Access Transformation Rapid Payer Response online portal. 30 participants from France, Germany, Spain, the UK and the USA were recruited based on their expertise.

Results

Participants agreed that the most common uses of RWE are to confirm efficacy and safety results from randomized controlled trials and to reevaluate the projected utilization of an oncology therapy. We found variability in other reported uses of RWE.

Conclusion

The organizations developing RWE should ensure that their plans recognize the heterogeneity in payer perceptions. A survey from the Market Access Transformation RPR portal queried decision-makers from five countries about the value of real-world evidence in oncology therapy reassessment. Participants agreed that RWE can confirm efficacy/safety and reevaluate utilization, but other uses varied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical OncologyNeoplasmsHumansTechnology Assessment, BiomedicalSurveys and QuestionnairesFranceUnited StatesGermanyEvidence-Based MedicineUnited KingdomSpain

Stichwörter der Autor:innen

oncologypayerreal-world evidencereassessmentsurvey

Autor:innen und Institutionen

  • Global Evidence & Value Development Oncology, EMD Serono, Inc., Rockland, MA 02370, USA, an affiliate of Merck KGaA.
  • Market Access Transformation, Fleet, GU51 2UJ, UK.
  • Value & Evidence, Pfizer, New York, NY 10001-2192, USA.
  • Genesis Research Group, Hoboken, NJ 07030, USA.

ORCID-Profile: Murtuza Bharmal, Chris L Pashos

Förderung

  • Merck (CrossRef Funder ID: 10.13039/100009945)
  • Pfizer

Zitieren

APA

Bharmal, M., Katsoulis, I., Chang, J., Graham, A., Stavropoulou, A., Jhingran, P., & Pashos, C. L. (2024). Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries. Future Oncology. https://doi.org/10.2217/fon-2023-1004

Vancouver

Bharmal M, Katsoulis I, Chang J, Graham A, Stavropoulou A, Jhingran P, et al. Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries. Future Oncology. 2024. doi:10.2217/fon-2023-1004

BibTeX
@article{Bharmal2024,
  author = {Bharmal, Murtuza and Katsoulis, Ioannis and Chang, Jane and Graham, Alex and Stavropoulou, Apostolina and Jhingran, Priti and Pashos, Chris L},
  title = {Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-1004}
}
Kostenlos starten →